These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30662379)

  • 1. Spectral Photon-Counting Molecular Imaging for Quantification of Monoclonal Antibody-Conjugated Gold Nanoparticles Targeted to Lymphoma and Breast Cancer: An
    Moghiseh M; Lowe C; Lewis JG; Kumar D; Butler A; Anderson N; Raja A
    Contrast Media Mol Imaging; 2018; 2018():2136840. PubMed ID: 30662379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions.
    Hainfeld JF; O'Connor MJ; Dilmanian FA; Slatkin DN; Adams DJ; Smilowitz HM
    Br J Radiol; 2011 Jun; 84(1002):526-33. PubMed ID: 21081567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
    Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
    Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
    Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
    Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells.
    Carpin LB; Bickford LR; Agollah G; Yu TK; Schiff R; Li Y; Drezek RA
    Breast Cancer Res Treat; 2011 Jan; 125(1):27-34. PubMed ID: 20217215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
    Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
    Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
    Scollard DA; Chan C; Holloway CM; Reilly RM
    Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
    Ulaner GA; Hyman DM; Ross DS; Corben A; Chandarlapaty S; Goldfarb S; McArthur H; Erinjeri JP; Solomon SB; Kolb H; Lyashchenko SK; Lewis JS; Carrasquillo JA
    J Nucl Med; 2016 Oct; 57(10):1523-1528. PubMed ID: 27151988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer.
    Chattopadhyay N; Cai Z; Pignol JP; Keller B; Lechtman E; Bendayan R; Reilly RM
    Mol Pharm; 2010 Dec; 7(6):2194-206. PubMed ID: 20973534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
    Menendez JA; Vazquez-Martin A; Colomer R; Brunet J; Carrasco-Pancorbo A; Garcia-Villalba R; Fernandez-Gutierrez A; Segura-Carretero A
    BMC Cancer; 2007 May; 7():80. PubMed ID: 17490486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
    Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
    J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.
    Ito K; Mitsunaga M; Nishimura T; Kobayashi H; Tajiri H
    Oncotarget; 2016 Mar; 7(12):14143-52. PubMed ID: 26909859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
    Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J
    Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer.
    Kubota T; Kuroda S; Kanaya N; Morihiro T; Aoyama K; Kakiuchi Y; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
    Nanomedicine; 2018 Aug; 14(6):1919-1929. PubMed ID: 29885899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.